Non classé

UPDATE on DESTINY-Gastric02 Study: Trastuzumab Deruxtecan Continues to Demonstrate Benefit in Metastatic Gastric and Gastro-oesophageal Cancer

Read

A Combination of Targeted Therapy Drugs Improves Both Progression-Free Survival (PFS) and Overall Survival (OS) in Unresectable Hepatocellular Carcinoma (uHCC)

Read

DiCE Award Helps EuropaColon Polska Pregnancy Project Come to Life

EuropaColon Polska launches campaign for pregnant women on the risks and signs and symptoms of CRC with help from DiCE Award

Read

New Normal, Same Cancer Campaign Continues

New Normal, same Cancer campaign continues – with specific materials on certian tumour types also now available

Read

Welcome to A.R.CA.D – Our New French Member

Welcome to our new Member organisation A.R.CA.D from France – strengthening our collective voice in fighting digestive cancers for patients!<...

Read

Grants to Civil Society Orgs Addressed in Collective Response to EU Consultation

DiCE adds the patient voice to the EPF response to EU Consultation – adding key point on grants to CSO’s

Read

DiCE Launches Project to Educate Patients and Healthcare Professionals on Biomarkers in Colorectal Cancer

DiCE launches educational project on biomarkers – Colorectal cancer: getting personal can be lifesaving

Read

Immunotherapy drug nivolumab approved in Europe as adjuvant treatment for patients with oesophageal cancer

The European Commission (EC) recently approved nivolumab (Opdivo®) for the treatment of patients with oesophageal or gastro-oesophageal junction (...

Read

DiCE Projects Ensure Patient Involvement in Basic and Clinical Research

Discover our projects bringing patient involvement into basic and clinical cancer research – overviews to be given in our Masterclass

Read

All.Can – Cancer Care Efficiency Resources for DiCE Members

All.Can – Cancer Efficiency Resources for DiCE Members

Read